Search | Clinical Trials Finder

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • Palm Springs, California + 15 more

Conditions: B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Fludeoxyglucose F-18, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab; Procedure · Drug · Biological + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography; Procedure · Biological · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 6
States / cities: Rochester, Minnesota • St Louis, Missouri • Hackensack, New Jersey + 3 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Epcoritamab, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 68
States / cities: Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more

Conditions: Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
Interventions: Epcoritamab; Biological
Lead sponsor: Izidore Lossos, MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
Interventions: ONC-PluReceptor NK cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Interventions: Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin; Drug
Lead sponsor: Taylor Brooks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Follicular Lymphoma (FL)
Interventions: Epcoritamab, Rituximab, Lenalidomide; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 31
States / cities: Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more

Conditions: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma
Interventions: GEN3009, Epcoritamab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Denver, Colorado • Cleveland, Ohio • Columbus, Ohio + 4 more

Conditions: Adult Burkitt Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab, Vincristine; Procedure · Drug · Biological
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions: Epcoritamab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 70
States / cities: Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more

Conditions: Randomized, Phase 2, Epcoritamab, Watch & Wait, Untreated, Tumor Burden, Follicular Lymphoma
Interventions: Epcoritamab, Observation; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab and Lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate; Drug · Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Diffuse Large B Cell Lymphoma
Interventions: Epcoritamab, Glofitamab, External Beam Radiation Therapy; Drug · Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Gemcitabine, Oxaliplatin, Positron Emission Tomography, Rituximab; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Duarte, California • Newnan, Georgia • Zion, Illinois

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: Reem Karmali; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Follicular Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Other · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
Interventions: AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab; Procedure · Drug
Lead sponsor: Dipenkumar Modi; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Interventions: Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab combined with polatuzumab, cyclophosphamide, doxorubicin, and prednisone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Newton, Massachusetts

Conditions: Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
Interventions: Zanubrutinib, Rituximab, Epcoritamab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio

Conditions: Leukemia, Chronic Lymphocytic, Richter Syndrome
Interventions: epcoritamab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Outpatient Epcoritamab in Large B-cell Lymphoma

Epco, Zanu, Ritux for R/R FL or MZL

Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome